Meta-analysis of randomized controlled trials for the development of the International Federation for Surgery of Obesity and Metabolic Disorders-European Chapter (IFSO-EC) guidelines on multimodal strategies for the surgical treatment of obesity.

De Luca M, Belluzzi A, Angrisani L, Bandini G, Becattini B, Bueter M, Carrano FM, Chiappetta S, Cohen RV, Copaescu C, Di Lorenzo N, Emous M and 21 more

Show all authors

Felsenreich DM, Fried M, Himpens J, Iannelli A, Navarra G, Nienhuijs S, Olmi S, Parmar C, Prager G, Pujol-Rafols J, Ragghianti B, Ribeiro R, Ruiz-Úcar E, Sakran N, Salminen P, Scoccimarro D, Stenberg E, Stier C, Taskin HE, Puy RV, Monami M

Diabetes, obesity & metabolism8 Apr 2025Cited by 14 (Europe PMC)

PMID40197859DOI10.1111/dom.16352PepBankPUB-40197859

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

01HumanSystematic reviewEfficacy outcome
In people undergoing metabolic bariatric surgery, liraglutide added to surgery was associated with greater percentage excess weight loss than surgery alone (P=0.008).
In plain wordsIn people having bariatric surgery, adding liraglutide was linked to greater excess weight loss than surgery alone.
Peptide
Liraglutide
Outcome
IncreasePercentage excess weight loss
Study
n: not reported in source
Comparator
Metabolic bariatric surgery alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
P-value
0.008
isolated liraglutide add-on contrast
Source sentences
Summary
The addition of liraglutide only to MBS was associated with a greater %EWL%, but not %TWL and TBWL (p = 0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a meta-analysis including all RCTs enrolling patients undergoing different MBS procedures add-on to other anti-obesity strategies (LSI, MT, OMM or ES) versus MBS alone, with a duration of at least 6 months.
Summary · context
The primary outcome was BMI at the end-point; secondary end-points included percentage total and excess weight loss (%TWL%, and EBWL%), total weight loss (TWL), fasting plasma glucose (FPG), HbA1c, surgical and non-surgical severe adverse events (SAE), mortality,
Report a problemFND-4019785902
02HumanSystematic reviewEfficacy outcome
In people undergoing metabolic bariatric surgery, liraglutide added to surgery was not associated with greater percentage total weight loss than surgery alone.
In plain wordsIn people having bariatric surgery, adding liraglutide did not improve total weight loss compared with surgery alone.
Peptide
Liraglutide
Outcome
No significant changePercentage total weight loss
Study
n: not reported in source
Comparator
Metabolic bariatric surgery alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The addition of liraglutide only to MBS was associated with a greater %EWL%, but not %TWL and TBWL (p = 0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a meta-analysis including all RCTs enrolling patients undergoing different MBS procedures add-on to other anti-obesity strategies (LSI, MT, OMM or ES) versus MBS alone, with a duration of at least 6 months.
Summary · context
The primary outcome was BMI at the end-point; secondary end-points included percentage total and excess weight loss (%TWL%, and EBWL%), total weight loss (TWL), fasting plasma glucose (FPG), HbA1c, surgical and non-surgical severe adverse events (SAE), mortality,
Report a problemFND-4019785903
03HumanSystematic reviewEfficacy outcome
In people undergoing metabolic bariatric surgery, liraglutide added to surgery was not associated with greater total body weight loss than surgery alone.
In plain wordsIn people having bariatric surgery, adding liraglutide did not improve body weight loss compared with surgery alone.
Peptide
Liraglutide
Outcome
No significant changeTotal body weight loss
Study
n: not reported in source
Comparator
Metabolic bariatric surgery alone
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The addition of liraglutide only to MBS was associated with a greater %EWL%, but not %TWL and TBWL (p = 0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a meta-analysis including all RCTs enrolling patients undergoing different MBS procedures add-on to other anti-obesity strategies (LSI, MT, OMM or ES) versus MBS alone, with a duration of at least 6 months.
Summary · context
The primary outcome was BMI at the end-point; secondary end-points included percentage total and excess weight loss (%TWL%, and EBWL%), total weight loss (TWL), fasting plasma glucose (FPG), HbA1c, surgical and non-surgical severe adverse events (SAE), mortality,
Report a problemFND-4019785904
04HumanSystematic reviewEfficacy outcome
In people undergoing metabolic bariatric surgery, liraglutide added to surgery significantly reduced end-point HbA1c compared with surgery alone (P=0.007).
In plain wordsIn people having bariatric surgery, adding liraglutide lowered HbA1c compared with surgery alone.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Metabolic bariatric surgery alone
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
P-value
0.007
isolated liraglutide add-on contrast
Source sentences
Summary
Three trials evaluated end-point HbA1c, showing a significant reduction in favour of liraglutide as an add-on therapy to MBS (p = 0.007).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a meta-analysis including all RCTs enrolling patients undergoing different MBS procedures add-on to other anti-obesity strategies (LSI, MT, OMM or ES) versus MBS alone, with a duration of at least 6 months.
Summary · context
The primary outcome was BMI at the end-point; secondary end-points included percentage total and excess weight loss (%TWL%, and EBWL%), total weight loss (TWL), fasting plasma glucose (FPG), HbA1c, surgical and non-surgical severe adverse events (SAE), mortality,
Report a problemFND-4019785905

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people undergoing metabolic bariatric surgery, adding liraglutide or an endobariatric procedure was associated with lower BMI at end-point than surgery alone (P=0.040).
In plain wordsIn people having bariatric surgery, adding liraglutide or an endobariatric procedure was linked to lower BMI than surgery alone.
Peptide
Liraglutide
Outcome
DecreaseBMI at end-point
Study
n: not reported in source
Comparator
Metabolic bariatric surgery alone
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
P-value
0.04
pooled BMI contrast
Source sentences
Summary
The addition of either OMM (i.e., liraglutide) or EP (i.e., intragastric balloon-IB, endosleeve-ES) to MBS was associated with a significantly lower BMI at the end-point (p = 0.040).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a meta-analysis including all RCTs enrolling patients undergoing different MBS procedures add-on to other anti-obesity strategies (LSI, MT, OMM or ES) versus MBS alone, with a duration of at least 6 months.
Summary · context
The primary outcome was BMI at the end-point; secondary end-points included percentage total and excess weight loss (%TWL%, and EBWL%), total weight loss (TWL), fasting plasma glucose (FPG), HbA1c, surgical and non-surgical severe adverse events (SAE), mortality,
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4019785901
06HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across included MBS trials of surgery with or without adjunct interventions including liraglutide, no mortality was reported; no native-specific death estimate was provided.
In plain wordsAcross bariatric-surgery trials with or without adjuncts including liraglutide, no deaths were reported; native-specific counts were unstated.
Peptide
Liraglutide
Outcome
Not applicableMortality
Study
n: not reported in source
Analysis
Secondary
Outcome group
Mortality · Whole body
Source sentences
Summary
There was no mortality.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a meta-analysis including all RCTs enrolling patients undergoing different MBS procedures add-on to other anti-obesity strategies (LSI, MT, OMM or ES) versus MBS alone, with a duration of at least 6 months.
Summary · context
secondary end-points included percentage total and excess weight loss (%TWL%, and EBWL%), total weight loss (TWL), fasting plasma glucose (FPG), HbA1c, surgical and non-surgical severe adverse events (SAE), mortality,
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4019785906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.